This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
The study, which is the first phase-1 vaccine study in HIV infected people in Ireland, is also the first of a planned number of early intervention studies to be carried out in the Wellcome Trust-HRB Clinical Research Facility, a joint enterprise between Trinity College Dublin and St James’s Hospital.
The research team are evaluating the safety and the ability of a new vaccine to produce an immune response against Hepatitis C. Previous healthy volunteer studies in the University of Oxford have shown encouraging results. If effective, this vaccine could also be made available to other high risk groups such as intravenous drug users.
The study, which will run for 20 months, will follow 20 patients have in Dublin and St Gallen, Switzerland. Patients will be given two vaccines eight weeks apart and then followed closely to assess safety and the development of immune responses to Hepatitis C following vaccination. The vaccines being tested in this study are called AdCh3NSmut1 and MVA-NSmut and have been developed by ReiThera Srl and GlaxoSmithKline Biologicals SA.
Read more….http://medicalxpress.com/news/2015-11-scientists-homing-hepatitis-vaccine.html